# Integer Holdings Corp: Form 10-Q for the period ended Oct 1, 2021

- Company: [Integer Holdings Corp](/companies/itgr.md) (CIK 1114483)
- Form: 10-Q
- Filed: 2021-10-28
- Accepted by EDGAR: Oct 28, 2021, 16:04 ET
- Period: 2021-10-01
- Accession: 0001114483-21-000031
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1114483/000111448321000031/itgr-20211001.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1114483/000111448321000031/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-10-01.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2021-07-03 to 2021-10-01 | $305.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2021-01-01 to 2021-10-01 | $908.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2021-07-03 to 2021-10-01 | $223.7m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2021-01-01 to 2021-10-01 | $653.0m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2021-07-03 to 2021-10-01 | $81.9m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2021-01-01 to 2021-10-01 | $255.1m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2021-07-03 to 2021-10-01 | $34.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2021-01-01 to 2021-10-01 | $105.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2021-07-03 to 2021-10-01 | $33.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2021-01-01 to 2021-10-01 | $107.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2021-07-03 to 2021-10-01 | $10.1m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2021-01-01 to 2021-10-01 | $26.1m | us-gaap:InterestExpense |
| Income tax | 3 months, 2021-07-03 to 2021-10-01 | $1.1m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2021-01-01 to 2021-10-01 | $5.9m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2021-07-03 to 2021-10-01 | $22.1m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2021-01-01 to 2021-10-01 | $73.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2021-07-03 to 2021-10-01 | $0.66 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2021-01-01 to 2021-10-01 | $2.20 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2021-07-03 to 2021-10-01 | $0.67 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2021-01-01 to 2021-10-01 | $2.21 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2021-07-03 to 2021-10-01 | 33,309,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2021-01-01 to 2021-10-01 | 33,250,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2021-01-01 to 2021-10-01 | $117.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2021-01-01 to 2021-10-01 | $29.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2021-10-01 | $25.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-10-01 | $442.6m | us-gaap:AssetsCurrent |
| Total assets | at 2021-10-01 | $2.35bn | us-gaap:Assets |
| Current liabilities | at 2021-10-01 | $156.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-10-01 | $1.02bn | us-gaap:Liabilities |
| Long-term debt | at 2021-10-01 | $610.4m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2021-10-01 | $20.3m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2021-10-01 | $1.33bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 49,685 characters.

*This Quarterly Report on Form 10-Q should be read in conjunction with the disclosures included in our Annual Report on Form 10-K for the year ended December 31, 2020. In addition, please read this section in conjunction with our Condensed Consolidated Financial Statements and Notes to Condensed Consolidated Financial Statements contained herein.*

### Forward-Looking Statements

Some of the statements contained in this report and other written and oral statements made from time to time by us and our representatives are not statements of historical or current fact. As such, they are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We have based these forward-looking statements on our current expectations, and these statements are subject to known and unknown risks, uncertainties and assumptions. Forward-looking statements include statements relating to:

- recovery from the COVID-19 global pandemic;
- future development and expected growth of our business and industry, including expansion of our manufacturing capacity;
- our ability to execute our business model and our business strategy, including completion and integration of current or future acquisition targets;
- having available sufficient cash and borrowing capacity to meet working capital, debt service and capital expenditure requirements for the next twelve months; and
- projected capital spending.

You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “projects” or “continue” or variations or the negative of these terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those stated or implied by these forward-looking statements. In evaluating these statements and our prospects, you should carefully consider the factors set forth below. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary factors and to others contained throughout this report.

Although it is not possible to create a comprehensive list of all factors that may cause actual results to differ from the results expressed or implied by our forward-looking statements or that may affect our future results, some of these factors and other risks and uncertainties that arise from time to time are described in Item 1A “Risk Factors” of our Annual Report on Form 10-K and in other periodic filings with the Securities and Exchange Commission and include the following:

- the impact of the COVID-19 global pandemic;
- our dependence upon a limited number of customers;
- pricing pressures that we face from customers;
- our reliance on third party suppliers for raw materials, key products and subcomponents;
- the potential for harm to our reputation caused by quality problems related to our products;
- the dependence of our energy market-related revenues on the conditions in the oil and natural gas industry;
- interruptions in our manufacturing operations;
- our dependence upon our information technology systems and our ability to prevent cyber-attacks and other failures;
- our ability to attract, train and retain a sufficient number of qualified associates;
- our dependence upon our senior management team and technical personnel;
- the intense competition we face and our ability to successfully market our products;
- our ability to respond to changes in technology;
- our ability to develop new products and expand into new geographic and product markets;
- our ability to successfully identify, make and integrate acquisitions to expand and develop our businesses in accordance with expectations;
- our significant amount of outstanding indebtedness and our ability to remain in compliance with financial and other covenants under our senior secured credit facilities;
- economic and credit market uncertainties that could interrupt our access to capital markets, borrowings or financial transactions;
- market and financial risks related to our international operations and sales;
- our complex international tax profile;
- our ability to realize the full value of our intangible assets;
- regulatory issues resulting from products complaints, recalls or regulatory audits;
- the potential of becoming subject to product liability or intellectual property claims;
- our ability to protect our intellectual property and proprietary rights;
- our ability and the cost to comply with environmental regulations;
- our ability to comply with customer-driven policies and third-party standards or certification requirements;

\- 27 -

- our ability to obtain necessary licenses for new technologies;
- legal and regulatory risks from our international operations; and
- the fact that the healthcare industry is highly regulated and subject to various regulatory changes.

Except as required by applicable law, the Company assumes no obligation to update forward-looking statements in this report whether to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial conditions or prospects, or otherwise.

In this Form 10-Q, references to “Integer,” “we,” “us,” “our” and the “Company” mean Integer Holdings Corporation and its subsidiaries, unless the context indicates otherwise.

### Our Business

Integer Holdings Corporation is one of the largest medical device outsource (“MDO”) manufacturers in the world serving the cardiac, neuromodulation, vascular, orthopedics, advanced surgical and portable medical markets. We also develop batteries for high-end niche applications in the non-medical energy, military, and environmental markets. Our vision is to enhance the lives of patients worldwide by being our customers’ partner of choice for innovative technologies and services.

We organize our business into two reportable segments, Medical and Non-Medical, and derive our revenues from four principal product lines. The Medical segment includes the Cardio & Vascular, Cardiac & Neuromodulation and Advanced Surgical, Orthopedics & Portable Medical product lines and the Non-Medical segment comprises the Electrochem product line. For more information on our segments, please refer to Note 14 “Segment Information” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report.

The third quarter and first nine months of 2021 ended on October 1 and consisted of 91 days and 274 days, respectively. The third quarter and first nine months of 2020 ended on October 2 and consisted of 91 days and 276 days, respectively.

### Impact of COVID-19

Beginning in early March 2020, the global spread of the novel coronavirus (“COVID-19”) created significant uncertainty and worldwide economic disruption. Specific impacts to our business include labor shortages, disruptions in the supply chain, delayed or reduced customer orders and sales, restrictions on associates’ ability to travel or work, and delays in shipments to and from certain countries. The extent to which COVID-19 will continue to impact our operations will depend on future developments, which remain highly uncertain and difficult to predict, including, among others, the duration of the outbreak, the effectiveness and utilization of vaccines for COVID-19 and its variants, new information that may emerge concerning the severity of COVID-19 and the actions, especially those taken by governmental authorities to contain the pandemic or treat its impact. As pandemic-related events continue to evolve, additional impacts may arise that we are not aware of currently. Any prolonged material disruption of our labor force, suppliers, manufacturing, or customers could materially impact our consolidated financial position, results of operations or cash flows.

### Business Acquisition

On February 19, 2020, we acquired certain assets and liabilities of InoMec Ltd. (“InoMec”), a privately-held company based in Israel that specializes in the research, development and manufacturing of medical devices, including minimally invasive tools, delivery systems, tubing and catheters, surgery tools, drug-device combination, laser combined devices, and tooling and production. The acquisition enables us to create a research and development center in Israel, closer to the customer base in the region.

Refer to Note 2 “Business Acquisition” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information about this acquisition.

\- 28 -

### Strategic Overview

We continue to take steps to better align our resources in order to invest to grow and protect, and preserve our portfolio of products. In addition to our portfolio strategy, we continue to execute our six key operational strategic imperatives designed to drive excellence in everything we do:

- Sales Force Excellence: We are focusing our efforts within the commercial organization to further improve our efficiency and effectiveness and to align with product line growth strategies and customer needs. These activities are about getting more out of the capabilities we already have, and increasing individual accountability and clarity of ownership, while serving customers more effectively.
- Market Focused Innovation: We are ensuring we get the most return on our research and development investments. We are focused on having a clear picture of how we spend our money so we can increase investments to drive future growth.
- Manufacturing Excellence: The goal is to deliver world-class operational performance in the areas of safety, quality, delivery and overall efficiency. We want to transition our manufacturing into a competitive advantage through a single, enterprise-wide manufacturing structure known as the Integer Production System. This system will provide standardized systems and processes by leveraging best practices and applying them across all of our global sites.
- Business Process Excellence: We are taking a systematic approach to driving excellence in everything we do by standardizing, optimizing and ultimately sustaining all of our processes.
- Leadership Capability: We have a robust plan to make leadership a competitive advantage for us, and as the success rate is higher with internal hires, we are focusing on finding and developing leaders from within the Company to build critical capabilities for future success.
- Performance Excellence: We are raising the bar on associate performance to maximize our impact. This includes aligning key roles with critical capabilities, positioning the best talent against the biggest work, and putting tools and processes in place to provide higher financial rewards for top performers, so our top performers can see increased results in pay for increased results in their performance.

We believe we are well-positioned within the medical technology and MDO manufacturing market and that there is a robust pipeline of opportunities to pursue. We have expanded our medical device capabilities and are excited about opportunities to partner with customers to drive innovation. We believe we have the scale and global presence, supported by world-class manufacturing and quality capabilities, to capture these opportunities. We are confident in our capabilities as one of the largest MDO manufacturers, with a long history of successfully integrating companies, driving down costs and growing revenues over the long-term. Ultimately, our strategic vision is to drive shareholder value by enhancing the lives of patients worldwide by being our customers’ partner of choice for innovative technologies and services.

\- 29 -

### Financial Overview

Net income for the third quarter and first nine months of 2021 was $22.1 million, or $0.66 per diluted share, and $73.0 million, or $2.20 per diluted share, respectively, compared to $30.3 million, or $0.92 per diluted share, and $61.8 million, or $1.87 per diluted share for the third quarter and first nine months of 2020, respectively. These variances are primarily the result of the following:

- Sales for the third quarter and first nine months of 2021 increased $69.6 million and $103.6 million, respectively, when compared to the same periods in 2020. During the third quarter of 2021 we continued to see the demand for many of our products recover from the impacts of the COVID-19 pandemic.
- Gross profit for the third quarter and first nine months of 2021 increased $23.9 million and $42.6 million, respectively, primarily from higher sales volume and production efficiencies.
- Operating expenses for the third quarter and first nine months of 2021 increased $30.6 million and $28.6 million, respectively, when compared to the same periods in 2020, primarily because of a $28.2 million gain recognized in connection with a patent litigation judgment offsetting third quarter of 2020 Selling, general and administrative expenses. See “*Patent Litigation”* below for additional information.
- Interest expense for the third quarter of 2021 increased $0.7 million compared to the same period in 2020, primarily due to higher losses from extinguishment of debt, partially offset by lower outstanding debt balances. Interest expense for the first nine months of 2021 decreased $2.9 million compared to the same period in 2020, primarily due to lower outstanding debt balances, partially offset by higher losses from extinguishment of debt.
- During the third quarter and first nine months of 2021, we recognized a gain on equity investments of $0.2 million and a net loss of $1.9 million, respectively, compared to a gain of $2.2 million and net gains of $4.0 million, respectively, for the third quarter and first nine months of 2020. Gains and losses on equity investments are generally unpredictable in nature.
- Other (income) loss, net for the third quarter and first nine months of 2021 were losses of approximately $0.1 million, compared to a loss of $1.2 million and income of $0.2 million, respectively, for the third quarter and first nine months of 2020, primarily due to fluctuations in foreign currency gains and losses in the respective periods.
- We recorded provisions for income taxes for the third quarter and first nine months of 2021 of $1.1 million and $5.9 million, respectively, compared with provisions for income taxes of $1.1 million and $6.4 million, respectively, for the third quarter and first nine months of 2020. The changes in income tax were primarily due to relative changes in pre-tax income and the impact of discrete tax items.

### Patent Litigation

In April 2013, we commenced an action against a competitor alleging they had infringed on the our patents by manufacturing and selling filtered feedthrough assemblies used in implantable pacemakers and cardioverter defibrillators that incorporate our patented technology.

Following four trials and an appeal, the United States Court of Appeals for the Federal Circuit affirmed, in all respects, a judgment in our favor. We received proceeds related to the judgment of $28.9 million in October 2020, and after recognizing certain related expenses, recognized a net gain of $28.2 million, which is recorded in Selling, *g*eneral and administrative expenses. The proceeds were used to pay down a portion of our Revolving Credit Facility.

\- 30 -

### Our Financial Results

The following tables present selected financial information derived from our Condensed Consolidated Financial Statements, contained in Item 1 of this report, for the periods presented (dollars in thousands, except per share).

| Medical Sales: | Three Months Ended October 1, 2021 | October 2, 2020 | Change $% |  |
| --- | ---: | ---: | ---: | ---: |
| Cardio & Vascular | 160,858 | $124,596 | $36,262 | 29.1% |
| Cardiac & Neuromodulation | 106,543 | 72,909 | 33,634 | 46.1% |
| Advanced Surgical, Orthopedics & Portable Medical | 28,720 | 30,179 | (1,459) | (4.8)% |
| Total Medical Sales | 296,121 | 227,684 | 68,437 | 30.1% |
| **Non-Medical** | 9,453 | 8,258 | 1,195 | 14.5% |
| Total sales | 305,574 | 235,942 | 69,632 | 29.5% |
| Cost of sales | 223,702 | 178,009 | 45,693 | 25.7% |
| Gross profit | 81,872 | 57,933 | 23,939 | 41.3% |
| Gross profit as a % of sales | 26.8% | 24.6% |  |  |
| Operating expenses: |  |  |  |  |
| Selling, general and administrative (“SG&A”)(a) | 34,269 | 3,609 | 30,660 | NM |
| SG&A as a % of sales | 11.2% | 1.5% |  |  |
| Research, development and engineering (“RD&E”) | 12,050 | 11,892 | 158 | 1.3% |
| RD&E as a % of sales | 3.9% | 5.0% |  |  |
| Other operating expenses | 2,463 | 2,674 | (211) | (7.9)% |
| Total operating expenses | 48,782 | 18,175 | 30,607 | 168.4% |
| Operating income | 33,090 | 39,758 | (6,668) | (16.8)% |
| Operating income as a % of sales | 10.8% | 16.9% |  |  |
| Interest expense | 10,053 | 9,368 | 685 | 7.3% |
| Gain on equity investments | (152) | (2,234) | 2,082 | (93.2)% |
| Other loss, net | 10 | 1,224 | (1,214) | (99.2)% |
| Income before taxes | 23,179 | 31,400 | (8,221) | (26.2)% |
| Provision for income taxes | 1,113 | 1,058 | 55 | 5.2% |
| Effective tax rate | 4.8% | 3.4% |  |  |
| Net income | $22,066 | $30,342 | $(8,276) | (27.3)% |
| Net income as a % of sales | 7.2% | 12.9% |  |  |
| Diluted earnings per share | $0.66 | $0.92 | $(0.26) | (28.3)% |

(a) Selling, general and administrative expenses for the third quarter of 2020 includes a gain of $28.2 million recognized in connection with a patent litigation judgment. See “*Patent Litigation”* in the Financial Overview section for additional information.

NM Calculated amount not meaningful

\- 31 -

### MANAGEMENT'S DISCUSSION AND ANALYSIS

| Medical Sales: | Nine Months Ended October 1, 2021 | October 2, 2020 | Change $% |  |
| --- | ---: | ---: | ---: | ---: |
| Cardio & Vascular | $462,632 | $432,885 | $29,747 | 6.9% |
| Cardiac & Neuromodulation | 334,700 | 252,404 | 82,296 | 32.6% |
| Advanced Surgical, Orthopedics & Portable Medical | 83,380 | 92,041 | (8,661) | (9.4)% |
| Total Medical Sales | 880,712 | 777,330 | 103,382 | 13.3% |
| **Non-Medical** | 27,352 | 27,153 | 199 | 0.7% |
| Total Sales | 908,064 | 804,483 | 103,581 | 12.9% |
| Cost of sales | 652,960 | 591,985 | 60,975 | 10.3% |
| Gross profit | 255,104 | 212,498 | 42,606 | 20.1% |
| Gross profit as a % of sales | 28.1% | 26.4% |  |  |
| Operating expenses: |  |  |  |  |
| SG&A(a) | 105,150 | 73,969 | 31,181 | 42.2% |
| SG&A as a % of sales | 11.6% | 9.2% |  |  |
| RD&E | 39,249 | 37,879 | 1,370 | 3.6% |
| RD&E, Net as a % of sales | 4.3% | 4.7% |  |  |
| Other operating expenses | 3,657 | 7,631 | (3,974) | (52.1)% |
| Total operating expenses | 148,056 | 119,479 | 28,577 | 23.9% |
| Operating income | 107,048 | 93,019 | 14,029 | 15.1% |
| Operating margin | 11.8% | 11.6% |  |  |
| Interest expense | 26,117 | 29,002 | (2,885) | (9.9)% |
| (Gain) loss on equity investments, net | 1,867 | (3,954) | 5,821 | (147.2)% |
| Other (income) loss, net | 129 | (233) | 362 | (155.4)% |
| Income before taxes | 78,935 | 68,204 | 10,731 | 15.7% |
| Provision for income taxes | 5,916 | 6,373 | (457) | (7.2)% |
| Effective tax rate | 7.5% | 9.3% |  |  |
| Net income | $73,019 | $61,831 | $11,188 | 18.1% |
| Net income as a % of sales | 8.0% | 7.7% |  |  |
| Diluted earnings per share | $2.20 | $1.87 | $0.33 | 17.6% |

(a) Selling, general and administrative expenses for the nine months ended October 2, 2020 includes a gain of $28.2 million recognized in connection with a patent litigation judgment. See “*Patent Litigation”* in the Financial Overview section for additional information.

\- 32 -

### MANAGEMENT'S DISCUSSION AND ANALYSIS

### Product Line Sales

For the third quarter and first nine months of 2021, Cardio & Vascular sales increased $36.3 million, or 29%, and $29.7 million, or 7%, respectively, versus the comparable 2020 periods. Cardio & Vascular sales for the third quarter and first nine months of 2021 reflect the continued recovery from the negative impact of COVID-19, with strong increases across all Cardio & Vascular markets driven by market demand, particularly in the peripheral vascular and electrophysiology markets. During the third quarter and first nine months of 2021, price changes increased Cardio & Vascular sales by $0.3 million and lowered sales by $0.6 million, respectively, in comparison to the 2020 periods. Foreign currency exchange rate fluctuations increased Cardio & Vascular sales for the third quarter and first nine months of 2021 by $0.1 million and $2.1 million, respectively, in comparison to the 2020 periods, primarily due to U.S. dollar fluctuations relative to the Euro.

For the third quarter and first nine months of 2021, Cardiac & Neuromodulation sales increased $33.6 million, or 46%, and $82.3 million or 33%, respectively, versus the comparable 2020 periods. Cardiac & Neuromodulation sales for the third quarter and first nine months of 2021 reflect the continued recovery from the negative impact of COVID-19. Sales in the cardiac rhythm management market and neuromodulation market saw double-digit increases when comparing the three and nine month periods of 2021 to the same periods last year. During the third quarter and first nine months of 2021, price reductions lowered Cardiac & Neuromodulation sales by $3.0 million and $8.5 million, respectively, in comparison to the 2020 periods. Foreign currency exchange rate fluctuations did not have a material impact on Cardiac & Neuromodulation sales during the third quarter and first nine months of 2021 in comparison to 2020.

In addition to Portable Medical sales, Advanced Surgical, Orthopedic & Portable Medical includes sales to the acquirer of our former AS&O Product Line, under supply agreements entered into as part of the divestiture. For the third quarter and first nine months of 2021, Advanced Surgical, Orthopedic & Portable Medical sales decreased $1.5 million, or 5%, and $8.7 million or 9%, respectively, versus the comparable 2020 periods as Portable Medical ventilator and patient monitoring components sales declined. During the third quarter and first nine months of 2021, price reductions lowered Advanced Surgical, Orthopedic & Portable Medical sales by $0.5 million and $0.4 million, respectively, in comparison to the 2020 periods. Foreign currency exchange rate fluctuations did not have a material impact on Advanced Surgical, Orthopedic & Portable Medical sales during the third quarter and first nine months of 2021 in comparison to the 2020 periods.

For the third quarter and first nine months of 2021, Non-Medical sales increased $1.2 million, or 14%, and $0.2 million or 1%, respectively, versus the comparable 2020 periods. The sales increases were driven by the recovery of the energy market, which offset the negative impact of COVID-19 that continued into the beginning of 2021. Price reductions and foreign currency exchange rate fluctuations did not have a material impact on Non-Medical sales during the third quarter and first nine months of 2021 in comparison to the 2020 periods.

### Gross Profit

Changes to gross profit as a percentage of sales (“Gross Margin”) from the prior year were due to the following:

|  | Change From Prior Year Three Months | Nine Months |
| --- | ---: | ---: |
| Price(a) | (0.7)% | (0.7)% |
| Mix(b) | 0.9 | 0.9 |
| Production efficiencies and volume(c) | 2.0 | 1.4 |
| Customer Bankruptcy(d) | — | 0.1 |
| Total percentage point change to gross profit as a percentage of sales | 2.2% | 1.7% |

(a) Our Gross Margin for the third quarter and first nine months of 2021 was negatively impacted by price reductions given to our larger OEM customers in return for long-term volume commitments.

(b) Amounts represent the impact to our Gross Margin attributable to changes in the mix of product sales during the periods.

(c) Our Gross Margin for the third quarter and first nine months of 2021 was positively impacted by higher sales volume and production efficiencies, mainly due to our Manufacturing Excellence imperative.

(d) In November 2019, one of our customers, Nuvectra Corporation, filed a voluntary Chapter 11 bankruptcy petition (the “Customer Bankruptcy”). During the first quarter of 2020, we incurred costs and recorded charges associated with the Customer Bankruptcy, primarily consisting of charges related to inventory recorded in cost of sales in our Condensed Consolidated Statements of Operations and Comprehensive Income.

\- 33 -

### SG&A Expenses

Changes to SG&A expenses from the prior year were due to the following (in thousands):

|  | Change From Prior Year Three Months | Nine Months |
| --- | ---: | ---: |
| Professional fees(a) | $721 | $(1,074) |
| Compensation and benefits(b) | 1,844 | 4,961 |
| Travel and entertainment(c) | 147 | (855) |
| Patent litigation gain(d) | 28,167 | 28,167 |
| All other SG&A(e) | (219) | (18) |
| Net increase in SG&A expenses | $30,660 | $31,181 |

(a) Professional fees increased during the third quarter and decreased during the first nine months of 2021 compared to the prior year periods, primarily due to the timing of legal costs.

(b) Compensation and benefits increased during the third quarter and first nine months of 2021 compared to the prior year periods, primarily due to higher incentive compensation expense.

(c) The increase in travel and entertainment expense during the third quarter of 2021 compared to the prior year period was a result of the resumption of limited travel during the the third quarter of 2021 as compared to a period of little to no travel during the the third quarter of 2020. Travel and entertainment expense decreased during the first nine months of 2021 compared to the prior year as a result of company travel being limited for the last 15 months due to COVID-19 travel restrictions.

(d) We recognized a net gain of $28.2 million during the third quarter of 2020 related to a patent litigation judgment. See “*Patent Litigation”* in the Financial Overview section for additional information.

(e) The net decrease in all other SG&A for the third quarter and first nine months of 2021 compared to the same periods of 2020 is primarily attributable to lower deprecation expense.

### RD&E

RD&E expense for the third quarter and first nine months of 2021 were $12.1 million and $39.2 million, respectively, compared to $11.9 million and $37.9 million, respectively, for the third quarter and first nine months of 2020. RD&E expenses are influenced by the number and timing of in-process projects and labor hours and other costs associated with these projects. Our research and development initiatives continue to emphasize new product development, product improvements, and the development of new technological platform innovations.

\- 34 -

### Other Operating Expenses

Other operating expenses (“OOE”) comprise the following (in thousands):

|  | Three Months Ended October 1, 2021 | October 2, 2020 | Nine Months Ended October 1, 2021 | October 2, 2020 |
| --- | ---: | ---: | ---: | ---: |
| Operational excellence(a) | $1,727 | $858 | $2,572 | $2,275 |
| Strategic reorganization and alignment(b) | — | — | — | 686 |
| Manufacturing alignment to support growth(c) | — | 36 | — | 224 |
| Acquisition and integration expenses(d) | 182 | 107 | 292 | 510 |
| Other general expenses(e) | 554 | 1,673 | 793 | 3,936 |
| Total other operating expenses | $2,463 | $2,674 | $3,657 | $7,631 |

(a) These projects focus on changing our organizational structure to match product line growth strategies and customer needs, transitioning our manufacturing process into a competitive advantage and standardizing and optimizing our business processes. Expenses for the third quarter and first nine months of 2021 and 2020 primarily consist of termination benefits.

(b) These initiatives primarily included aligning resources with our strategic direction, improving profitability to invest in accelerated growth and the expansion of a facility. These actions began in 2017 and were completed during the second quarter of 2020.

(c) These initiatives were designed to reduce costs, increase manufacturing capacity to accommodate growth and improve operating efficiencies by relocating certain manufacturing operations and expanding certain facilities. These actions began in 2017 and were completed during the fourth quarter of 2020.

(d) Amounts include expenses related to the purchase of certain assets and liabilities from business acquisitions. The 2020 amounts also includes a $0.5 million adjustment to reduce the fair value of acquisition-related contingent consideration liabilities. See Note 13 “Financial Instruments and Fair Value Measurements” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information related to the fair value measurement of the contingent consideration.

(e) Amounts include expenses related to other initiatives not described above, which relate primarily to integration and operational initiatives to reduce future costs and improve efficiencies. The 2020 amounts primarily include severance, information technology systems conversion expenses, expenses incurred in connection with the Customer Bankruptcy, and expenses related to the restructuring of certain legal entities of the Company.

Refer to Note 8 “Other Operating Expenses” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information regarding these initiatives.

### Interest Expense, Net

Interest expense consists primarily of cash interest and debt related charges, such as amortization of debt issuance costs and original issue discount. Interest expense for the third quarter of 2021 increased $0.7 million compared to the same period in 2020, primarily due to higher losses from extinguishment of debt, partially offset by lower outstanding debt balances. Interest expense for the first nine months of 2021 decreased $2.9 million compared to the same period in 2020, primarily due to lower outstanding debt balances, partially offset by higher losses from extinguishment of debt. During the second quarter of 2020 we borrowed an additional $160 million of our Revolving Credit Facility to protect against a prolonged pandemic coupled with the risk of financial market illiquidity. The additional borrowing on the Revolving Credit Facility was repaid during the third and fourth quarters of 2020. The weighted average interest rates on outstanding borrowings for the three months and nine months ended October 1, 2021 were 3.58% and 3.75%, respectively, compared to 3.60% and 3.83%, respectively, for the comparable periods in 2020.

\- 35 -

Debt related charges included in interest expense were $4.1 million and $6.5 million, respectively, during the third quarter and first nine months of 2021 compared to $1.1 million and $3.1 million, respectively, during the same periods in 2020. The increases in debt related charges are primarily attributable to accelerated write-offs of deferred issuance costs and unamortized discount (losses from extinguishment of debt) related to prepayments of portions of our Term Loan B facility made during the first nine months of 2021 and a write off of $3.3 million of deferred issuance costs and unamortized discount in connection with the refinancing of our credit facilities in September 2021. We had $3.3 million and $3.8 million, respectively, of losses from extinguishment of debt during the third quarter and first nine months of 2021 compared to no losses in the third quarter and first nine months of 2020. See Note 6 “Debt” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information pertaining to our debt.

As of October 1, 2021, approximately 24% of our principal amount of debt has been converted to fixed-rate borrowings with interest rate swaps, in comparison to approximately 27% as of December 31, 2020. We enter into interest rate swap agreements in order to reduce our exposure to fluctuations in the LIBOR rate. See Note 13 “Financial Instruments and Fair Value Measurements” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information pertaining to our interest rate swap agreements.

### (Gain) Loss on Equity Investments

During the third quarter and first nine months of 2021, we recognized a gain on equity investments of $0.2 million and a net loss of $1.9 million, respectively. During the third quarter and first nine months of 2020, we recognized a gain of $2.2 million and net gains of $4.0 million, respectively. Gains and losses on equity investments are generally unpredictable in nature. The amounts for both 2021 and 2020 relate to our share of equity method investee gains/losses including unrealized appreciation and depreciation of the underlying interests of the investee. As of October 1, 2021 and December 31, 2020, the carrying value of our equity investments was $23.4 million and $27.2 million, respectively. See Note 13 “Financial Instruments and Fair Value Measurements” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for further details regarding these investments.

### Other (Income) Loss, Net

Other (income) loss, net for the third quarter and first nine months of 2021 were losses of approximately $0.1 million, compared to a loss of $1.2 million and income of $0.2 million, respectively, for the third quarter and first nine months of 2020. Other (income) loss, net primarily includes gains/losses from the impact of exchange rates on transactions denominated in foreign currencies. Our foreign currency transaction gains/losses are based primarily on fluctuations of the U.S. dollar relative to the Euro, Mexican peso, Uruguayan peso, Malaysian ringgits, or Israeli shekel.

The impact of exchange rates on transactions denominated in foreign currencies included in Other income, net for the third quarter and first nine months of 2021 were net losses of approximately $0.1 million, compared to net losses of $1.2 million and net gains of $0.3 million for the third quarter and first nine months of 2020, respectively. We continually monitor our foreign currency exposures and seek to take steps to mitigate these risks. However, fluctuations in exchange rates could have a significant impact, positive or negative, on our financial results in the future.

\- 36 -

### Provision for Income Taxes

We recognized income tax expense of $1.1 million for the third quarter of 2021 on $23.2 million of income before taxes (effective tax rate of 4.8%), compared to an income tax expense of $1.1 million on $31.4 million of income before taxes (effective tax rate of 3.4%) for the same period of 2020. The income tax expense for the first nine months of 2021 was $5.9 million on $78.9 million of income before taxes (effective tax rate of 7.5%), compared to $6.4 million on income before taxes of $68.2 million (effective tax rate of 9.3%) for the same period of 2020. Income tax expense for the third quarter and first nine months of 2021 included $1.6 million and $6.1 million, respectively, of discrete tax benefits. Approximately $3.5 million of the discrete tax benefits recognized for first nine months of 2021 relate to the reversal of unrecognized tax benefits resulting from the effective settlement of tax audits during the second quarter of 2021.

There is a potential for volatility in our effective tax rate due to several factors including changes in the mix of pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, and settlements with taxing authorities and foreign currency fluctuations. We continue to closely monitor developments related to proposed changes in tax laws and tax rates, including current proposals for U.S. Tax Reform and a proposed 15% Minimum Global Tax Rate recently announced by the Organization for Economic Cooperation and Development (OECD). We currently have various tax planning initiatives in place and continuously evaluate planning strategies aimed at reducing our effective tax rate over the long term. This includes strategies to realize deferred tax assets that would otherwise expire unutilized.

Our effective tax rates for 2021 differ from the U.S. federal statutory tax rate of 21% due principally to the net impact of the Company’s earnings outside the U.S., which are generally taxed at rates that differ from the U.S federal rate, the Global Intangible Low-Taxed Income (“GILTI”) tax, the availability of tax credits, and the recognition of discrete tax benefits. The discrete tax benefits recognized for 2021 relate predominately to the reversal of unrecognized tax benefits resulting from the effective settlement of tax audits during the second quarter of 2021. The remainder of the discrete tax benefits relate predominately to excess tax benefits recognized upon vesting of RSUs or exercise of stock options during those quarters and favorable return to provision adjustments related to the 2020 tax year.

Our earnings outside the U.S. are generally taxed at blended rates that are marginally lower than the U.S. federal rate. The GILTI provisions require us to include foreign subsidiary earnings in excess of a deemed return on the foreign subsidiary’s tangible assets in our U.S. income tax return. The foreign jurisdictions in which we operate and where our foreign earnings are primarily derived, include Switzerland, Mexico, Uruguay, Malaysia and Ireland. While we are not currently aware of any material trends in these jurisdictions that are likely to impact our current or future tax expense, our future effective tax rates could be adversely affected by earnings being lower than anticipated in countries where we have lower effective tax rates and higher than anticipated in countries where we have higher effective tax rates, or by changes in tax laws or regulations. We regularly assess any significant exposure associated with increases in tax rates in international jurisdictions and adjustments are made as events occur that warrant adjustment to our tax provisions.

\- 37 -

### Liquidity and Capital Resources

*(dollars in thousands)*

|  | October 1, 2021 | December 31, 2020 |
| --- | ---: | ---: |
| Cash and cash equivalents | $25,472 | $49,206 |
| Working capital | $286,157 | $256,746 |
| Current ratio | 2.83 | 2.64 |

Cash and cash equivalents at October 1, 2021 decreased by $23.7 million from December 31, 2020, primarily as a result of net debt payments totaling $102.4 million, net purchases of property, plant and equipment of $29.6 million, mostly offset by cash generated by operating activities of $117.4 million.

Working capital increased by $29.4 million from December 31, 2020, primarily from positive working capital fluctuations associated with accounts receivable, contract assets and current long-term debt aggregating to $57.8 million, which were partially offset by fluctuations in cash and cash equivalents and accounts payable aggregating to $40.6 million. During the first nine months of 2021, accounts receivable increased mainly from higher sequential sales, and contract assets increased mainly due to a contract modification to add existing products and extend the contractual term, while current long-term debt decreased due to the refinancing of our term loan facilities during the third quarter of 2021. Cash and cash equivalents decreased primarily from net debt payments in the first nine months of 2021, while accounts payable increased mainly from the timing of supplier payments and higher sequential inventory purchases.

At October 1, 2021, $17.0 million of our cash and cash equivalents were held by foreign subsidiaries. We intend to limit our distributions from foreign subsidiaries to previously taxed income or current period earnings. If distributions are made utilizing current period earnings, we will record foreign withholding taxes in the period of the distribution.

### Summary of Cash Flow

*(in thousands)*

| Cash provided by (used in): | Nine Months Ended October 1, 2021 | October 2, 2020 |
| --- | ---: | ---: |
| Operating activities | $117,410 | $110,239 |
| Investing activities | (29,630) | (44,932) |
| Financing activities | (112,067) | 21,698 |
| Effect of foreign currency exchange rates on cash and cash equivalents | 553 | (597) |
| Net change in cash and cash equivalents | $(23,734) | $86,408 |

***Operating Activities –*** During the first nine months of 2021, we generated cash from operations of $117.4 million, compared to $110.2 million for the first nine months of 2020. The increase of $7.2 million was due to an increase of $28.2 million in net income adjusted for non-cash items such as depreciation and amortization, partially offset by a decrease of $21.0 million in cash flow provided by changes in operating assets and liabilities.

The increase in net income adjusted for non-cash items such as depreciation and amortization is primarily from higher gross profit from sales growth and margin expansion in the current period. The decrease in cash flow provided by changes in operating assets and liabilities is primarily the result of fluctuations in accounts receivable and accounts payable caused by declining sales in the prior year versus sales growth in the current period. This dynamic caused a significant prior year benefit to operating cash flow from the collection of accounts receivable in a period of declining sales, which resulted from the COVID-19 pandemic.

***Investing Activities –*** The $15.3 million decrease in net cash used in investing activities was primarily attributable to decreased purchases of property, plant and equipment of $5.5 million, intangible assets of $4.6 million, and $5.2 million of cash paid for the acquisition of certain assets and liabilities from InoMec Ltd. in the first quarter of 2020.

***Financing Activities –*** Net cash used in financing activities for the first nine months of 2021, was $112.1 million compared to $21.7 million provided by financing activities for the first nine months of 2020. Financing activities during the first nine months of 2021 primarily included debt payments of $102.4 million, compared to net borrowings of $21.9 million for the comparable 2020 period.

\- 38 -

During the second quarter of 2020, we borrowed an additional $160 million of our Revolving Credit Facility to protect against a prolonged pandemic coupled with the risk of financial market illiquidity. We subsequently paid down $135 million of the additional borrowing during the third quarter of 2020 and the remainder in the fourth quarter of 2020.

***Capital Structure –*** As of October 1, 2021, our capital structure consists of $631 million of debt, net of deferred debt issuance costs and unamortized discounts, outstanding under our Senior Secured Credit Facilities and 33 million shares of common stock outstanding. As of October 1, 2021, we have access to $357.0 million of borrowing capacity under our Revolving Credit Facility, available for normal course of business and letters of credit, and are authorized to issue up to 100 million shares of common stock and 100 million shares of preferred stock. As of October 1, 2021, our contractual debt service obligations for the remainder of 2021, consisting of principal and interest on our outstanding debt, are estimated to be $9.2 million. Actual principal and interest payments may be higher if, for instance, the applicable interest rates on our Senior Secured Credit Facilities increase, we borrow additional amounts on our Revolving Credit Facility, or we pay principal amounts in excess of the required minimums reflected in the contractual debt service obligations above.

Based on current expectations, we believe that our projected cash flows provided by operations, available cash and cash equivalents and borrowings under our Revolving Credit Facility are sufficient to meet our working capital, debt service and capital expenditure requirements for the next twelve months. If our future financing needs increase, we may need to arrange additional debt or equity financing. We continually evaluate and consider various financing alternatives to enhance or supplement our existing financial resources, including our Senior Secured Credit Facilities. However, we cannot be assured that we will be able to enter into any such arrangements on acceptable terms or at all.

***Credit Facilities*** - On September 2, 2021, we refinanced our existing debt by entering into a new credit agreement. See Note 6 “Debt” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for details regarding our debt refinancing during the quarter ended October 1, 2021.

As of October 1, 2021, we had Senior Secured Credit Facilities that consist of (i) a $400 million revolving credit facility (the “Revolving Credit Facility”), which had available borrowing capacity of $357.0 million, (ii) a term loan A facility (the “TLA Facility”) with outstanding principal balance of $250 million, and (iii) a term loan B facility (the “TLB Facility”) with outstanding principal balance of $350 million. The Revolving Credit Facility and TLA Facility mature on September 2, 2026. The TLB Facility matures on September 2, 2028. The Senior Secured Credit Facilities include a mandatory prepayment provision customary for credit facilities of its nature.

The Revolving Credit Facility and TLA Facility contain covenants requiring that we maintain (i) a total net leverage ratio not to exceed 5.50:1.00 (stepping down to 5.00:1.00 for the third fiscal quarter of 2023 through maturity and subject to increase in certain circumstances following certain qualified acquisitions) and (ii) an interest coverage ratio of at least 2.50:1.00. As of October 1, 2021, we were in compliance with these financial covenants. The TLB Facility does not contain any financial maintenance covenants. As of October 1, 2021, our total net leverage ratio, calculated in accordance with our Senior Secured Credit Facilities agreement, was approximately 2.1 to 1.0. For the twelve month period ended October 1, 2021, our interest coverage ratio, calculated in accordance with our Senior Secured Credit Facilities agreement, was approximately 10.7 to 1.0.

Failure to comply with these financial covenants would result in an event of default as defined under the Revolving Credit Facility and TLA Facility unless waived by the lenders. An event of default may result in the acceleration of our indebtedness. As a result, management believes that compliance with these covenants is material to us.

See Note 6 “Debt” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for a further information on the Company’s outstanding debt.

### Off-Balance Sheet Arrangements

We do not currently have off balance sheet arrangements that have or are reasonably likely to have a material current or future effect on our Condensed Consolidated Financial Statements.

### Impact of Recently Issued Accounting Standards

In the normal course of business, we evaluate all new accounting pronouncements issued by the Financial Accounting Standards Board, Securities and Exchange Commission, or other authoritative accounting bodies to determine the potential impact they may have on our Condensed Consolidated Financial Statements. See Note 1 “Basis of Presentation” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information about these recently issued accounting standards and their potential impact on our financial condition or results of operations.

\- 39 -

### Contractual Obligations

There have been no significant changes to our contractual obligations during the quarter ended October 1, 2021 as compared to those disclosed in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2020.

### Critical Accounting Policies and Estimates

The preparation of our Condensed Consolidated Financial Statements in accordance with accounting principles generally accepted in the U.S. requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements and accompanying notes. Our estimates, assumptions and judgments are based on historical experience and various other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amount of assets and liabilities that are not readily apparent from other sources. Making estimates, assumptions and judgments about future events is inherently unpredictable and is subject to significant uncertainties, some of which are beyond our control. Management believes the estimates, assumptions and judgments employed and resulting balances reported in the Condensed Consolidated Financial Statements are reasonable; however, actual results could differ materially.

There have been no significant changes to the critical accounting policies and estimates as compared to those disclosed in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2020.

\- 40 -

## Market risk

As filed, 607 characters.

Refer to information appearing under the caption “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of this Form 10-Q. Furthermore, a discussion of market risk exposures is included in Part II, Item 7A, Quantitative and Qualitative Disclosure about Market Risk, of the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Other than the uncertainties resulting from the global pandemic, there have been no material changes in reported market risk since the inclusion of this discussion in the Company’s Annual Report on Form 10-K referenced above.

## Controls and procedures

As filed, 1,416 characters.

a. Evaluation of Disclosure Controls and Procedures

Our management, including the principal executive officer and principal financial officer, evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) related to the recording, processing, summarization and reporting of information in our reports that we file with the Securities and Exchange Commission as of October 1, 2021. These disclosure controls and procedures have been designed to provide reasonable assurance that material information relating to us, including our subsidiaries, is made known to our management, including these officers, by our employees, and that this information is recorded, processed, summarized, evaluated and reported, as applicable, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Based on their evaluation, as of October 1, 2021, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective.

b. Changes in Internal Control Over Financial Reporting

During the Company’s most recent fiscal quarter, there have been no changes in the Company’s internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

\- 41 -

## Risk factors

As filed, 171 characters.

There have been no material changes to the Company’s risk factors as previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Filed Oct 28, 2021.
Source: SEC EDGAR, the filing index for accession 0001114483-21-000031. Last ingested by Listed: Nov 11, 2026, 00:08 ET. No prices; not investment advice.
